JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, cilt.90, ss.458-468, 2019 (SCI İndekslerine Giren Dergi)
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.